

9 April 2025

SUPPLY CHAIN RESILIENCE AND U.S. POLICY MOMENTUM SUPPORTS RESPIRI REMOTE PATIENT MONITORING GROWTH STRATEGY

Highlights:

- **Policy Tailwind:** U.S. Health Secretary Robert F. Kennedy Jr. (“RFK Jr.”) endorses AI and telehealth solutions as critical enablers of access and quality care—an affirmation of Respiri’s Connected Care model.
- **Strategic Alignment:** RFK Jr. identifies virtual care technologies as capable of delivering “concierge-level” services in rural communities, consistent with Respiri’s mission and delivery model.
- **Supply Chain Resilience:** Recently announced U.S. tariffs on Chinese-manufactured medical devices will have minimal impact on Respiri’s operations, with over two years of wheezo® inventory already in the U.S.
- **Cost Absorption Strategy:** Expected tariff-related cost increases (approx. US\$30 per other medical device) will be absorbed by Respiri, not passed on to clients. These costs represent only an additional c.13 days of reimbursement fee-for-service revenue per enrolled patient.
- **Uninterrupted Commercial Execution:** No disruption to customer pricing or engagement. All current and planned ACO deployments remain on schedule.

Respiri Limited (ASX:RSH; OTCQB:RSHUF) (“Respiri”), an eHealth Company delivering Connected Care and Chronic Condition Management through remote patient monitoring (“RPM”) across the U.S. healthcare system, today announced that recent developments in U.S. health policy and international trade reinforce the company’s commercial strategy and operational robustness.

In remarks delivered at a recent Senate session, U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. spotlighted the transformative potential of AI, telehealth, and virtual care platforms in providing efficient and effective patient services—particularly in rural and underserved communities. Secretary Kennedy advocated strongly for scaling these technologies through the healthcare system.

This policy direction directly supports Respiri’s Connected Care business model and the adoption of its RPM-enabled platforms, including wheezo® and other medical devices, by Medicare Shared Savings Program (MSSP) Accountable Care Organizations (ACOs), Independent Physician Associations (IPAs), and other healthcare organisation provider networks.

As the company scales, Respiri confirms that the recently announced U.S. tariffs on Chinese-manufactured medical devices will have no material impact on business operations. Respiri has already more than two years’ worth of wheezo® inventory in the United States. Additionally, although the tariff may increase supply costs by ~US\$30 per other medical devices, the company will absorb the increase internally, equating to less than half a month’s worth of RPM reimbursement revenue per patient—ensuring no change to client pricing or margin exposure or disruption to existing and new Respiri clients.

Marjan Mikel, Respiri CEO said, *“Comments from Secretary Kennedy highlight a sea change in U.S. healthcare – one where virtual care is no longer a ‘nice-to-have’, but a national priority. Respiri is at the forefront of this shift, delivering scalable, clinically integrated RPM solutions that improve outcomes and reduce cost. Meanwhile, our prudent inventory management ensures we remain relatively immune to supply-side disruption from recent US tariff changes ”*

-ENDS-

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited – A Revolutionary Remote Healthcare Solutions Provider

Respiri Limited (ASX:RSH, OTCQB:RSHUF) is leading the charge in transforming healthcare delivery in the US. As an innovator in medical devices and MedTech, we combine state-of-the-art technologies with unparalleled clinical expertise. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We're revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at www.respiri.co/au

About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Respiri, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respiri™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit <https://respiri.co/us> or for [wheezo®](http://wheezo.com)

Respiri Limited is headquartered in Melbourne with offices in New York City and Miami.

wheezo® is a registered trademark of Respiri Limited

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.